Geodesic
Database of Chemical Substances the Potential Biomarkers of Diseases with the Meaning in Noninvasive Diagnostics
Matematičeskaâ biologiâ i bioinformatika, Tome 6 (2011), pp. 250-263.

Voir la notice de l'article provenant de la source Math-Net.Ru

There is a potential use of volatile biomarkers for noninvasive diagnostics in medicine. Creating a common information resource based on the integrated data from different sources of chemical compounds with the potential diagnostic meaning facilitates the planning of experiments on noninvasive diagnostics. The database containing information on potential biomarkers of diseases at the level of metabolites, enzymes, transcription factors that allows planning the experiments on noninvasive diagnostics of diseases was developed. Using database ProMeDiA on the example of aspergillosis infection caused by Aspergillus fumigatus, was undertaken the analysis of volatile compounds involved in the reactions regulated by human enzymes, associated with aspergillosis, and by A. fumigatus enzymes. The potential volatile biomarkers of aspergillosis infection were proposed. On the example of metabolism changes in rheumatoid arthritis the possibility of using database ProMeDiA for metabolic networks reconstruction, which allows identifying potential biomarkers of diseases, was demonstrated. 
@article{MBB_2011_6_a3,
     author = {O. V. Saik and M. P. Moshkin and M. N. Baldin and V. M. Groyznov and V. A. Kozlov and S. N. Samorokov and P. S. Demenkov and V. A. Ivanisenko and N. A. Kolchanov},
     title = {Database of {Chemical} {Substances} the {Potential} {Biomarkers} of {Diseases} with the {Meaning} in {Noninvasive} {Diagnostics}},
     journal = {Matemati\v{c}eska\^a biologi\^a i bioinformatika},
     pages = {250--263},
     publisher = {mathdoc},
     volume = {6},
     year = {2011},
     language = {ru},
     url = {http://geodesic.mathdoc.fr/item/MBB_2011_6_a3/}
}
TY  - JOUR
AU  - O. V. Saik
AU  - M. P. Moshkin
AU  - M. N. Baldin
AU  - V. M. Groyznov
AU  - V. A. Kozlov
AU  - S. N. Samorokov
AU  - P. S. Demenkov
AU  - V. A. Ivanisenko
AU  - N. A. Kolchanov
TI  - Database of Chemical Substances the Potential Biomarkers of Diseases with the Meaning in Noninvasive Diagnostics
JO  - Matematičeskaâ biologiâ i bioinformatika
PY  - 2011
SP  - 250
EP  - 263
VL  - 6
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/item/MBB_2011_6_a3/
LA  - ru
ID  - MBB_2011_6_a3
ER  - 
%0 Journal Article
%A O. V. Saik
%A M. P. Moshkin
%A M. N. Baldin
%A V. M. Groyznov
%A V. A. Kozlov
%A S. N. Samorokov
%A P. S. Demenkov
%A V. A. Ivanisenko
%A N. A. Kolchanov
%T Database of Chemical Substances the Potential Biomarkers of Diseases with the Meaning in Noninvasive Diagnostics
%J Matematičeskaâ biologiâ i bioinformatika
%D 2011
%P 250-263
%V 6
%I mathdoc
%U http://geodesic.mathdoc.fr/item/MBB_2011_6_a3/
%G ru
%F MBB_2011_6_a3
O. V. Saik; M. P. Moshkin; M. N. Baldin; V. M. Groyznov; V. A. Kozlov; S. N. Samorokov; P. S. Demenkov; V. A. Ivanisenko; N. A. Kolchanov. Database of Chemical Substances the Potential Biomarkers of Diseases with the Meaning in Noninvasive Diagnostics. Matematičeskaâ biologiâ i bioinformatika, Tome 6 (2011), pp. 250-263. http://geodesic.mathdoc.fr/item/MBB_2011_6_a3/

[1] Corradi M., Mutti A., “Exhaled breath analysis: from occupational to respiratory medicine”, Acta Biomed, 76 (2005), 20–29

[2] Phillips M., Cataneo R.N., Ditkoff B.A., “Volatile markers of breast cancer in the breath”, Breast J., 9 (2003), 184–191 <ext-link ext-link-type='doi' href='https://doi.org/10.1046/j.1524-4741.2003.09309.x'>10.1046/j.1524-4741.2003.09309.x</ext-link>

[3] Pabst F., Miekisch W., Fuchs P., Kischkel S., Schubert J.K., “Monitoring of oxidative and metabolic stress during cardiac surgery by means of breath biomarkers: an observational study”, J. Cardiothorac Surg., 2 (2007), 37–44 <ext-link ext-link-type='doi' href='https://doi.org/10.1186/1749-8090-2-37'>10.1186/1749-8090-2-37</ext-link>

[4] Phillips M., Herrera J., Krishnan S., Zain M., Greenberg J., Cataneo R.N., “Variation in volatile organic compounds in the breath of normal humans”, Journal of Chromatography B., 729 (1999), 75–88 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0378-4347(99)00127-9'>10.1016/S0378-4347(99)00127-9</ext-link>

[5] Gordon S.M., Szidon J.P., Krotoszynski B.K., Gibbons R.D., O'Neill H.J., “Volatile organic compounds in exhaled air from patients with lung cancer”, Clin. Chem., 31 (1985), 1278–1282

[6] Phillips M., Gleeson K., Hughes J.M., Greenberg J., Cataneo R.N., Baker L., McVay W.P., “Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study”, Lancet, 353 (1999), 1930–1933 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0140-6736(98)07552-7'>10.1016/S0140-6736(98)07552-7</ext-link>

[7] Ligor M., Ligor T., Bajtarevic A., Ager C., Pienz M., Klieber M., Denz H., Fiegl M., Hilbe W., Weiss W., Lukas P., Jamnig H., Hackl M., Buszewski B., Miekisch W., Schubert J., Amann A., “Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry”, Clin. Chem. Lab. Med., 47:5 (2009), 550–560 <ext-link ext-link-type='doi' href='https://doi.org/10.1515/CCLM.2009.133'>10.1515/CCLM.2009.133</ext-link>

[8] Novak B.J., Blake D.R., Meinardi S., Rowland F.S., Pontello A., Cooper D.M., Galassetti P.R., “Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes”, Proc. Natl. Acad. Sci. USA, 104:40 (2007), 15613–15618 <ext-link ext-link-type='doi' href='https://doi.org/10.1073/pnas.0706533104'>10.1073/pnas.0706533104</ext-link>

[9] Probert C.S., Jones P.R., Ratcliffe N.M., “A novel method for rapidly diagnosing the causes of diarrhea”, Gut, 53:1 (2004), 58–61 <ext-link ext-link-type='doi' href='https://doi.org/10.1136/gut.53.1.58'>10.1136/gut.53.1.58</ext-link>

[10] Tangerman A., Meuwese-Arends M.T., Jansen J.B., “Cause and composition of foetor hepaticus”, Lancet, 343 (1994), 483–490 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0140-6736(94)92729-4'>10.1016/S0140-6736(94)92729-4</ext-link>

[11] Van den Velde S., Nevens F., Van Hee P., van Steenberghe D., Quirynen M., “GC-MS analysis of breath odor compounds in liver patients”, Journal of Chromatography B., 875 (2008), 344–348 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.jchromb.2008.08.031'>10.1016/j.jchromb.2008.08.031</ext-link>

[12] Braden B., Lembcke B., Kuker W., Caspary W.F., “13C-breath tests: current state of the art and future directions”, Dig. Liver Dis., 39 (2007), 795–805 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.dld.2007.06.012'>10.1016/j.dld.2007.06.012</ext-link>

[13] Chen X., Xu F., Wang Y., Pan Y., Lu D., Wang P., Ying K., Chen E., Zhang W., “A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis”, Cancer, 110:4 (2007), 835–844 <ext-link ext-link-type='doi' href='https://doi.org/10.1002/cncr.22844'>10.1002/cncr.22844</ext-link>

[14] Poli D., Carbognani P., Corradi M., Goldoni M., Acampa O., Balbi B., Bianchi L., Rusca M., Mutti A., “Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study”, Respir. Res., 14 (2005), 6–71

[15] Abaffy T., Duncan R., Riemer D.D., Tietje O., Elgart G., Milikowski C., DeFazio R.A., “Differential Volatile Signatures from Skin, Naevi and Melanoma: A Novel Approach to Detect a Pathological Process”, PLoS One, 5:11 (2010), 13813–13825 <ext-link ext-link-type='doi' href='https://doi.org/10.1371/journal.pone.0013813'>10.1371/journal.pone.0013813</ext-link>

[16] Qin T., Liu H., Song Q., Song G., Wang H., Pan Y., Xiong F., Gu K., Sun G., Chen Z., “The screening of volatile markers for hepatocellular carcinoma”, Cancer. Epidemiol. Biomarkers Prev., 19 (2010), 2247–2253 <ext-link ext-link-type='doi' href='https://doi.org/10.1158/1055-9965.EPI-10-0302'>10.1158/1055-9965.EPI-10-0302</ext-link>

[17] Liu C., Feng S., van Heemst J., McAdam K.G., “New insights into the formation of volatile compounds in mainstream cigarette smoke”, Anal. Bioanal. Chem., 396:5 (2010), 1817–1830 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s00216-010-3457-6'>10.1007/s00216-010-3457-6</ext-link>

[18] Filipiak W., Sponring A., Filipiak A., Ager C., Schubert J., Miekisch W., Amann A., Troppmair J., “TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro”, Cancer Epidemiol. Biomarkers Prev., 19:1 (2010), 182–195 <ext-link ext-link-type='doi' href='https://doi.org/10.1158/1055-9965.EPI-09-0162'>10.1158/1055-9965.EPI-09-0162</ext-link>

[19] Claudio G., Calder P.C., “Effects of Fat and Fatty Acid intake on inflammatory and immune responses: A critical review”, Ann. Nutr. Metab., 55 (2009), 123–139 <ext-link ext-link-type='doi' href='https://doi.org/10.1159/000228999'>10.1159/000228999</ext-link>

[20] Tkacova R., “Systemic Inflammation in Chronic Obstructive Pulmonary Disease: May Adipose Tissue Play a Role?”, Review of the Literature and Future Perspectives, Mediators of Inflammation, 2010 (2010), 585989–586000 <ext-link ext-link-type='doi' href='https://doi.org/10.1155/2010/585989'>10.1155/2010/585989</ext-link>

[21] Drager L.F., Jun J.C., Polotsky V.Y., “Metabolic consequences of intermittent hypoxia: Relevance to obstructive sleep apnea”, Best Practice & Research Clinical Endocrinology & Metabolism, 24 (2010), 843–851 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.beem.2010.08.011'>10.1016/j.beem.2010.08.011</ext-link>

[22] Fernández-Riejos P., Najib S., Santos-Alvarez J., Martín-Romero C., Pérez-Pérez A., González-Yanes C., Sánchez-Margalet V., “Role of Leptin in the Activation of Immune Cells”, Mediators of Inflammation, 2010 (2010), 568343–568351 <ext-link ext-link-type='doi' href='https://doi.org/10.1155/2010/568343'>10.1155/2010/568343</ext-link>

[23] Yoshino T., Kusunoki N., Tanaka N., Kaneko K., Kusunoki Y., Endo H., Hasunuma T., Kawai S., “Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis”, Intern. Med., 50:4 (2011), 269–275 <ext-link ext-link-type='doi' href='https://doi.org/10.2169/internalmedicine.50.4306'>10.2169/internalmedicine.50.4306</ext-link><ext-link ext-link-type='mr-item-id' href='http://mathscinet.ams.org/mathscinet-getitem?mr=1643367'>1643367</ext-link>

[24] Andreelli F., Jacquier D., Troy S., “Molecular aspects of insulin therapy in critically ill patients”, Curr. Opin. Clin. Nutr. Metab. Care, 9:2 (2006), 124–130 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/01.mco.0000214571.97933.0a'>10.1097/01.mco.0000214571.97933.0a</ext-link>

[25] Suryaprabha P., Das U.N., Ramesh G., Kumar K.V., Kumar G.S., “Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus”, Prostaglandins Leukot. Essent. Fatty Acids, 43:4 (1991), 251–255 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/0952-3278(91)90038-7'>10.1016/0952-3278(91)90038-7</ext-link>

[26] Jira W., Spiteller G., “Dramatic increase of linoleic acid peroxidation products by aging, atherosclerosis, and rheumatoid arthritis”, Adv. Exp. Med. Biol., 469 (1999), 479–483 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/978-1-4615-4793-8_70'>10.1007/978-1-4615-4793-8_70</ext-link>

[27] Calder P.C., “Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients”, Braz. J. Med. Biol. Res., 36:4 (2003), 433–446 <ext-link ext-link-type='doi' href='https://doi.org/10.1590/S0100-879X2003000400004'>10.1590/S0100-879X2003000400004</ext-link>

[28] Zhao X., Imig J.D., “Kidney CYP450 enzymes: biological actions beyond drug metabolism”, Curr. Drug. Metab., 4:1 (2003), 73–84 <ext-link ext-link-type='doi' href='https://doi.org/10.2174/1389200033336892'>10.2174/1389200033336892</ext-link>

[29] Pompeia C., Lima T., Curi R., “Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death?”, Cell Biochem. Funct., 21:2 (2003), 97–104 <ext-link ext-link-type='doi' href='https://doi.org/10.1002/cbf.1012'>10.1002/cbf.1012</ext-link>

[30] Kanadaşi M., Cayli M., Demirtaş M., Inal T., Demir M., Koç M., Avkaroǧullari M., Dönmez Y., Usal A., Alhan C.C., San M., “The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol”, Heart Vessels, 21:5 (2006), 291–297 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s00380-005-0901-1'>10.1007/s00380-005-0901-1</ext-link>

[31] Chae J.S., Kim O.Y., Paik J.K., Kang R., Seo W.J., Jeong T.S., Sweeney G., Lee S.H., Lee J.H., “Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome”, Atherosclerosis, 218:2 (2011), 499–506 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.atherosclerosis.2011.06.036'>10.1016/j.atherosclerosis.2011.06.036</ext-link><ext-link ext-link-type='mr-item-id' href='http://mathscinet.ams.org/mathscinet-getitem?mr=2805463'>2805463</ext-link>

[32] Saggini A., Anogeianaki A., Maccauro G., Tete S., Salini V., Caraffa A., Conti F., Fulcheri M., Galzio R., Shaik-Dasthagirisaheb Y.B., “Cholesterol, cytokines and diseases”, Int. J. Immunopathol. Pharmacol., 24:3 (2011), 567–581

[33] Koc H., King J., Teschl G., Unterkofler K., Teschl S., Mochalski P., Hinterhuber H., Amann A., “The role of mathematical modeling in VOC analysis using isoprene as a prototypic example”, J. Breath Res., 5:3 (2011), 37102–37109 <ext-link ext-link-type='doi' href='https://doi.org/10.1088/1752-7155/5/3/037102'>10.1088/1752-7155/5/3/037102</ext-link><ext-link ext-link-type='mr-item-id' href='http://mathscinet.ams.org/mathscinet-getitem?mr=2848842'>2848842</ext-link>

[34] Straub R.H., Weidler C., Demmel B., Herrmann M., Kees F., Schmidt M., Schölmerich J., Schedel J., “Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus”, Ann. Rheum. Dis., 63:8 (2004), 961–968 <ext-link ext-link-type='doi' href='https://doi.org/10.1136/ard.2003.014274'>10.1136/ard.2003.014274</ext-link>

[35] Hennebert O., Chalbot S., Alran S., Morfin R., “Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes”, J. Steroid Biochem. Mol. Biol., 104 (2007), 326–333 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.jsbmb.2007.03.026'>10.1016/j.jsbmb.2007.03.026</ext-link>

[36] Dulos J., van der Vleuten M.A., Kavelaars A., Heijnen C.J., Boots A.M., “CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines”, Arthritis Rheum., 52:3 (2005), 770–778 <ext-link ext-link-type='doi' href='https://doi.org/10.1002/art.20950'>10.1002/art.20950</ext-link>